Kim Smith-Whitley
Chief Tech/Sci/R&D Officer chez GLOBAL BLOOD THERAPEUTICS, INC.
Profil
Kim Smith-Whitley is currently the Director at the Sickle Cell Disease Association of America, Inc. and the Executive VP, Head-Research & Development at Global Blood Therapeutics, Inc. Dr. Smith-Whitley holds a doctorate degree from George Washington University.
Postes actifs de Kim Smith-Whitley
| Sociétés | Poste | Début |
|---|---|---|
| GLOBAL BLOOD THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/05/2021 |
| Sickle Cell Disease Association of America, Inc. | Director/Board Member | - |
Formation de Kim Smith-Whitley
| George Washington University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
| Sickle Cell Disease Association of America, Inc. | |
Global Blood Therapeutics, Inc.
 Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA. | Health Technology |
